The drug works by removing accumulated amyloid beta proteins in the brain, slowing the progress of the disease. Those ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Alzheimer's disease is the most common cause of dementia in the elderly and is characterized by abnormal deposits of amyloid-beta and tau proteins in the brain. This disease has a ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Prothena (PRTA – Research Report), retaining the price target of ...

In recent years, the focus of clinical development has been on immunotherapeutic compounds aimed at clearing brain ...

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble ...

In a major discovery, scientists have presented the first evidence of Alzheimer's disease transmission in living individuals.

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

single-injection once-monthly antibody delivered subcutaneously for the treatment of Alzheimer's disease that targets a key epitope at the N-terminus of amyloid beta (Aß) with high binding potency.

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by ...